Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors
NCT03726281
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
End of Agreement between BMS and SGHL
Conditions
Germ Cell Tumors
Interventions
DRUG:
Nivolumab
Sponsor
Hospital Beatriz Ângelo
Collaborators
[object Object]
[object Object]
[object Object]